Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II

Archives of Internal Medicine

Volumn 161, Issue 4, 2001, Pages 511-512

  Kaplan, N M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL TRIAL; COUGHING; DRUG SAFETY; DRUG UTILIZATION; HUMAN; HYPERTENSION; META ANALYSIS; NOTE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES;

EID: 0035952262     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.4.511     Document Type: Note

References (14)

1. Angiotensin II receptor antagonists
2. Treating high-risk hypertensive patients
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
4. 1999 World Health Organization-international Society of Hypertension Guidelines for the Management of Hypertension
5. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
6. Canadian recommendations for the management of hypertension
7. Choice of initial therapy for hypertension
8. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
9. Diuretics vs α-blockers for treatment of hypertension: Lessons from ALLHAT
10. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
11. All that glitters is not gold
12. Surrogate end points, health outcomes, andthe drug-approval process for the treatment of risk factors for cardiovascular disease
13. Claims of equivalence in medical research: Are they supported by the evidence?
14. ARB clinical trials around the turn of the millennium